This revision emphasized MSH6, which as also been observed mutted in hypermutated tumors in gliomas, prostate, and colorectal cancers (Cancer & Atlas, 2012; Johnson et al., 2017; Pritchard et al., 2014). Here, MSH6 is linked to glioma.